Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC)
| CAPS Rating |
|
|---|---|
| Open | $0.65 |
| Previous Close | $0.65 |
| Daily Range | $0.60 - $0.65 |
| 52-Week Range | $0.36 - $1.84 |
| Market Cap | $32.59M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 213,003 |
| Average Daily Volume | 0 |
CYCC
VS S&P 500 (SPY)
How do you think CYCC will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
CYCC Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
CYCC News and Commentary
- Blood Disease Drug Dacogen Gets Thumbs Down for Cancer Use – Minyanville
- Zacks #1 Rank Additions for Friday - Tale of the Tape – NASDAQ
- The Cancer Conference Trade: Picking Up Biotech Bargains – NASDAQ
- The Cancer Conference Trade: Picking Up Biotech Bargains – The Motley Fool
- Hot summer bottoms – Blog at The Motley Fool
- ASCO Pops and Drops – The Motley Fool
- Three Late-Stage Leukemia Company Previews for ASCO 2011 – Minyanville
- 3 Late-Stage Leukemia Company Previews for ASCO 2011 – SeekingAlpha
- To Partner or Not to Partner: That is the Question – SeekingAlpha
- 8 Stocks Near 52 Week Lows – SeekingAlpha
- Biotech Merger/Acquisition Activity Mixed During Major Conference – SeekingAlpha
- Pfizer, Adolor End Collaboration to Develop Pain Meds: Biotech's Latest Troubles – SeekingAlpha
- Five Biotech Stocks Worth Watching – SeekingAlpha
- 5 Biotechs Investors Should Be Watching – SeekingAlpha
- The Catalysts That Will Propel Cyclacel Pharmaceuticals Higher – SeekingAlpha
- Investment Opportunities in AML Frontline Therapies – SeekingAlpha
- UPDATE 1-Cyclacel to restate FY09 results to correct error – Reuters
- These Stocks Can Easily Double Your Money – The Motley Fool
- Why This Speculative Investment Could Ruin Your Savings – The Motley Fool
- Exelixis Secures Its Future – The Motley Fool
RSS Headlines
Fool UK
